Dr. Kenneth Anderson, a world-renowned myeloma spe­cialist, physician and re­searcher at Dana-Farber Cancer In­sti­tute, and Kraft Family Pro­fessor at Harvard Medical School, spoke with The Myeloma Beacon about his ap­proach to treating mul­ti­ple myeloma patients.

This article is the sec­ond part of a two-part series based on The Myeloma Beacon’s interview with Dr. Anderson.  It will cover Dr. Anderson’s thoughts on where myeloma treat­ment is headed in the com­ing years.  For more in­­for­ma­tion on Dr. Anderson’s cur­rent ap­proach to treating mul­ti­ple myeloma, please see part one of this series.

Emerging Therapies …

The results of a number of clinical trials for the treatment of multiple myeloma with Zolinza were presented at the American Society of Hematology (ASH) 2010 annual meeting. The trials, ranging from Phase 1 to Phase 3, studied Zolinza in combination with a variety of approved myeloma drugs for the treatment of both early and advanced stages of the disease.

Zolinza (vorinostat) is manufactured by Merck Pharmaceuticals.  It is currently approved for a certain type of lymphoma and is being investigated as a treatment for multiple myeloma (see related Beacon …

The American Society of He­ma­tol­ogy meeting swung into full gear yesterday. The day was full of invited talks and a poster session.

The morn­ing kicked off with an education session in which attendees could learn about sev­er­al myeloma-related topics.

The first pre­sen­ta­tion was by Dr. Ola Landgren from the National Cancer In­sti­tute and National In­sti­tutes of Health in Bethesda, Maryland. Dr. Landgren spoke about mono­clonal gam­mop­athy of undetermined sig­nif­i­cance (MGUS) and smol­der­ing myeloma, precursor dis­eases of mul­ti­ple myeloma.

A study pub­lished by Dr. Landgren last year showed that all mul­ti­ple myeloma patients have …

Friday, June 4, was the first day of this year's American Society of Clinical Oncology (ASCO) annual meeting in Chicago. Most of the big multiple myeloma news of the day came out of a poster session in the afternoon.

At "poster sessions," researchers present a poster-sized summary of their research in a small, 2 meter by 1 meter cubicle. Researchers and physicians mill about, taking pictures of the posters with their cell phone cameras or taking notes. Sometimes one or more of the contributing researchers are present to answer questions. More often than …

The results of a recent study suggest that Zolinza (vorinostat), in combination with Velcade (bortezomib), may be effective in patients with relapsed or refractory myeloma after prior treatment with Velcade. The study was published in the journal Clinical Lymphoma, Myeloma & Leukemia.

Velcade has become a standard first-line treatment option for multiple myeloma, but more and more patients are developing resistance to or relapsing after it. Zolinza is a new cancer drug that is already approved for a certain form of lymphoma. Preclinical trials suggest that it enhances …

The 2009 American Society of Hematology (ASH) Meeting showcased several presentations on Zolinza (vorinostat), a histone deacetylase inhibitor developed by Merck Pharmaceuticals that is currently investigated for the treatment of multiple myeloma.

Zolinza alters the way a cancer cell’s DNA creates proteins, which is important in cancer treatment because such a drug can slow down cell proliferation, minimize mutations in DNA and control cell death.

Zolinza With Revlimid And Dexamethasone

Preliminary data from an ongoing Phase 1 study suggest that the combination treatment of Zolinza, Revlimid (lenalidomide) and …

Description:

Zolinza (news articles), which is an approved drug for cutaneous T-cell lymphoma, is also being studied in combination with Velcade (bortezomib) for treatment of multiple myeloma. Zolinza is a histone deacetylase (HDAC) inhibitor, which modifies the …